Faculty Collaboration Database

Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Pract Radiat Oncol 2020;10(6):e495-e507

Date

02/18/2020

Pubmed ID

32061993

Pubmed Central ID

PMC7423616

DOI

10.1016/j.prro.2020.01.012

Scopus ID

2-s2.0-85082820455 (requires institutional sign-in at Scopus site)   43 Citations

Abstract

PURPOSE: To provide a detailed description of practical approaches to dose escalation in pancreatic cancer.

METHODS AND MATERIALS: The current paper represents an international collaborative effort of radiation oncologists from the MR-linac consortium with expertise in pancreatic dose escalation.

RESULTS: A 15-fraction hypofractionated intensity modulated radiation therapy (67.5 Gy in 15 fractions) and 5-fraction stereotactic body radiation therapy case (50 Gy in 5 fractions) are presented with information regarding patient selection, target volumes, organs at risk, dose constraints, and specific considerations regarding quality assurance. Additionally, we address barriers to dose escalation and briefly discuss future directions in dose escalation for pancreatic cancer, including particle therapy and magnetic resonance guided radiation therapy.

CONCLUSIONS: This article on dose escalation for pancreatic cancer may help to guide academic and community based physicians and to serve as a reference for future therapeutic trials.

Author List

Koay EJ, Hanania AN, Hall WA, Taniguchi CM, Rebueno N, Myrehaug S, Aitken KL, Dawson LA, Crane CH, Herman JM, Erickson B

Authors

Beth A. Erickson MD Professor in the Radiation Oncology department at Medical College of Wisconsin
William Adrian Hall MD Professor in the Radiation Oncology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Humans
Organs at Risk
Pancreatic Neoplasms
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
Radiotherapy, Intensity-Modulated